Investment focus
Inferred thesis
Auto-generated from public data. Not the firm's stated position.
Integra Holdings appears to focus on early-stage biotech investments, particularly in therapeutic modalities including immuno-oncology, genetic treatments, and advanced medical devices. Recent portfolio suggests a preference for companies addressing unmet needs in oncology and rare genetic diseases, with check sizes typically ranging from €0.1M to €1.5M at pre-seed and seed stages.
Generated 1 Oct 2026 from disclosed sectors, stages, and portfolio companies. Is this your firm? Claim the profile to correct it.
How to Pitch Integra Holdings
Recent investments
Auto-extracted from press releases.
- Round details unavailable
- Series B
Portfolio highlights
Similar investors
Focus and check size from the firm's website. Website reachable as of Oct 2026.
Ready to reach Integra Holdings?
Red-pen your deck first so the gaps are fixed before they read it. A fit check then scores your pitch against their thesis, stage and ticket, and an email draft uses their real deals and thesis, not a template.
Contact
Reach Integra Holdings through the links above. Pitchkit is not affiliated with the firm and does not forward pitches.